肿瘤坏死因子α抑制剂的免疫原性

Immunogenicity of Tumor Necrosis Factor-alpha Inhibitors

近年来肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)抑制剂广泛应用于风湿免疫性疾病的治疗,但临床医生对其免疫原性尚认识不足。越来越多的证据表明,TNF-α抑制剂的免疫原性对TNF-α抑制剂的药代动力学和临床疗效等均有影响。本文对TNF-α抑制剂免疫原性的产生机制、形成特点和监测方法等进行综述,相信加强监测和减少TNFα抑制剂的免疫原性具有重要的临床意义。

To date, millions of rheumatic patients have been treated with tumor necrosis factor-α （TNF-α） inhibitors for various indications. It is becoming increasingly clear that TNF-αinhibitors can be immunogenic, which may reduce efficacy or induce adverse effects. With the development of detective methods, we have an opportunity to study the anti-antibody immune response in human, and to manipulate immunogenicity in the future.